Literature DB >> 16652140

siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts.

J Dunne1, C Cullmann, M Ritter, N Martinez Soria, B Drescher, S Debernardi, S Skoulakis, O Hartmann, M Krause, J Krauter, A Neubauer, B D Young, O Heidenreich.   

Abstract

The chromosomal translocation t(8;21) is associated with 10-15% of all cases of acute myeloid leukaemia (AML). The resultant fusion protein AML1/MTG8 interferes with haematopoietic gene expression and is an important regulator of leukaemogenesis. We studied the effects of small interfering RNA (siRNA)-mediated AML1/MTG8 depletion on global gene expression in t(8;21)-positive leukaemic cell lines and in primary AML blasts using cDNA arrays, oligonucleotide arrays and real-time reverse transcription-polymerase chain reaction (RT-PCR). Suppression of AML1/MTG8 results in the increased expression of genes associated with myeloid differentiation, such as AZU1, BPI, CTSG, LYZ and RNASE2 as well as of antiproliferative genes such as IGFBP7, MS4A3 and SLA both in blasts and in cell lines. Furthermore, expression levels of several genes affiliated with drug resistance or indicative of poor prognosis AML (BAALC, CD34, PRG2, TSPAN7) are affected by AML1/MTG8 depletion. In conclusion, siRNA-mediated suppression of AML1/MTG8 cause very similar changes in gene expression pattern in t(8;21)-positive cell lines and in primary AML blasts. Furthermore, the results suggest that the specific targeting of AML1/MTG8 function may be a promising approach for complementing existing treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16652140     DOI: 10.1038/sj.onc.1209638

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

1.  AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.

Authors:  Wei Wang; Sven Schwemmers; Elizabeth O Hexner; Heike L Pahl
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

2.  RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms.

Authors:  Aejaz Nasir; James Helm; Leslie Turner; Dung-Tsa Chen; Jonathan Strosberg; Naiel Hafez; Evita B Henderson-Jackson; Pamela Hodul; Marilyn M Bui; Nelly A Nasir; Ardeshir Hakam; Mokenge P Malafa; Timothy J Yeatman; Domenico Coppola; Larry K Kvols
Journal:  Pancreas       Date:  2011-05       Impact factor: 3.327

3.  Genome-wide discovery of functional transcription factor binding sites by comparative genomics: the case of Stat3.

Authors:  Francesco Vallania; Davide Schiavone; Sarah Dewilde; Emanuela Pupo; Serge Garbay; Raffaele Calogero; Marco Pontoglio; Paolo Provero; Valeria Poli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-12       Impact factor: 11.205

4.  Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.

Authors:  Huining Kang; I-Ming Chen; Carla S Wilson; Edward J Bedrick; Richard C Harvey; Susan R Atlas; Meenakshi Devidas; Charles G Mullighan; Xuefei Wang; Maurice Murphy; Kerem Ar; Walker Wharton; Michael J Borowitz; W Paul Bowman; Deepa Bhojwani; William L Carroll; Bruce M Camitta; Gregory H Reaman; Malcolm A Smith; James R Downing; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

5.  High sensitivity and label-free oligonucleotides detection using photonic bandgap sensing structures biofunctionalized with molecular beacon probes.

Authors:  Ángela Ruiz-Tórtola; Francisco Prats-Quílez; Daniel González-Lucas; María-José Bañuls; Ángel Maquieira; Guy Wheeler; Tamas Dalmay; Amadeu Griol; Juan Hurtado; Jaime García-Rupérez
Journal:  Biomed Opt Express       Date:  2018-03-14       Impact factor: 3.732

6.  C/EBPα overrides epigenetic reprogramming by oncogenic transcription factors in acute myeloid leukemia.

Authors:  Justin Loke; Paulynn Suyin Chin; Peter Keane; Anna Pickin; Salam A Assi; Anetta Ptasinska; Maria Rosaria Imperato; Peter N Cockerill; Constanze Bonifer
Journal:  Blood Adv       Date:  2018-02-13

7.  AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.

Authors:  Jenny Dunne; Duncan M Gascoyne; T Andrew Lister; Hugh J M Brady; Olaf Heidenreich; Bryan D Young
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

8.  The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO.

Authors:  Fu-Sheng Chou; Andrea Griesinger; Mark Wunderlich; Shan Lin; Kevin A Link; Mahesh Shrestha; Susumu Goyama; Benjamin Mizukawa; Shuhong Shen; Guido Marcucci; James C Mulloy
Journal:  Blood       Date:  2012-02-14       Impact factor: 22.113

9.  Effects of the NUP98-DDX10 oncogene on primary human CD34+ cells: role of a conserved helicase motif.

Authors:  E R Yassin; A M Abdul-Nabi; A Takeda; N R Yaseen
Journal:  Leukemia       Date:  2010-03-25       Impact factor: 11.528

10.  A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO.

Authors:  Dani Osman; Vanessa Gobert; Frida Ponthan; Olaf Heidenreich; Marc Haenlin; Lucas Waltzer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.